475
Views
143
CrossRef citations to date
0
Altmetric
Original Research

Development and evaluation of thymoquinone-encapsulated chitosan nanoparticles for nose-to-brain targeting: a pharmacoscintigraphic study

, , , , , & show all
Pages 5705-5718 | Published online: 09 Nov 2012

Figures & data

Table 1 Pharmacokinetic profile of different formulations

Figure 1 Biodistribution study of (A) TQ solution (intravenous), (B) TQ solution (intranasal), and (C) chitosan nanoparticles encapsulating TQ (intranasal).

Figure 1 Biodistribution study of (A) TQ solution (intravenous), (B) TQ solution (intranasal), and (C) chitosan nanoparticles encapsulating TQ (intranasal).

Table 2 Results showing effects of different concentration of CS and TPP

Table 3 Particle size and particle size distribution of placebo formulations

Figure 2 Chitosan nanoshell showing possible interaction between chitosan and thymoquinone.

Figure 2 Chitosan nanoshell showing possible interaction between chitosan and thymoquinone.

Figure 3 Dynamic light scattering technique for determining the particle size distribution of placebo nanoparticles (A and B) and TQ-encapsulated nanoparticles (C), and zeta potential of TQ-encapsulated nanoparticles (D).

Figure 3 Dynamic light scattering technique for determining the particle size distribution of placebo nanoparticles (A and B) and TQ-encapsulated nanoparticles (C), and zeta potential of TQ-encapsulated nanoparticles (D).

Table 4 Particle size and particle size distribution of drug-loaded formulation

Table 5 Effect of TQ concentration on EE and LC

Figure 4 Transmission electron (A) and scanning electron (B) microscopy study of optimized nanoparticles.

Figure 4 Transmission electron (A) and scanning electron (B) microscopy study of optimized nanoparticles.

Figure 5 Differential scanning calorimetry (A) and X-ray diffraction spectroscopy (B) of thymoquinone (a), chitosan (b), physical mixture of thymoquinone–chitosan (c), and thymoquinone containing chitosan nanoparticles (d), respectively.

Figure 5 Differential scanning calorimetry (A) and X-ray diffraction spectroscopy (B) of thymoquinone (a), chitosan (b), physical mixture of thymoquinone–chitosan (c), and thymoquinone containing chitosan nanoparticles (d), respectively.

Table 6 Coefficient of correlation for optimized CS NPs

Figure 6 Ex vivo permeation of nanoparticles using porcine nasal mucosa.

Figure 6 Ex vivo permeation of nanoparticles using porcine nasal mucosa.

Table 7 In vitro radiolabeling stability in normal saline, rat plasma, and in rat brain homogenate

Table 8 Nose-to-brain drug-targeting parameters of different formulations

Figure 7 Concentration–time profile of thymoquinone (TQ) in plasma and brain after intravenous administration of TQ solution and intranasal administration of TQ solution and TQ nanoparticles, respectively (anti-clockwise).

Abbreviation: API, active pharmaceutical ingredient.

Figure 7 Concentration–time profile of thymoquinone (TQ) in plasma and brain after intravenous administration of TQ solution and intranasal administration of TQ solution and TQ nanoparticles, respectively (anti-clockwise).Abbreviation: API, active pharmaceutical ingredient.